BRPI0512583A - composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções - Google Patents

composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções

Info

Publication number
BRPI0512583A
BRPI0512583A BRPI0512583-9A BRPI0512583A BRPI0512583A BR PI0512583 A BRPI0512583 A BR PI0512583A BR PI0512583 A BRPI0512583 A BR PI0512583A BR PI0512583 A BRPI0512583 A BR PI0512583A
Authority
BR
Brazil
Prior art keywords
compositions
onychomycosis
infections
animal
treating
Prior art date
Application number
BRPI0512583-9A
Other languages
English (en)
Inventor
Frederick Dechow
Original Assignee
Mediquest Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/960,516 external-priority patent/US7740875B2/en
Application filed by Mediquest Therapeutics Inc filed Critical Mediquest Therapeutics Inc
Publication of BRPI0512583A publication Critical patent/BRPI0512583A/pt
Publication of BRPI0512583B1 publication Critical patent/BRPI0512583B1/pt
Publication of BRPI0512583B8 publication Critical patent/BRPI0512583B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A61K8/553—Phospholipids, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções é provida uma composição adequada para a liberação local de agentes cosméticos e/ou farmacêuticos na pele que contêm pelo menos dois solventes orgânicos biocompatíveis, um lipídio polar, um surfactante, uréia e um espessante, em que os solventes orgânicos incluem um éster e um álcool diídrico e/ou polihídrico. Também são reveladas composições que ainda contêm um agente cosmético e/ou farmacêutico, junto com a preparação e uso das mesmas.
BRPI0512583A 2004-10-08 2005-10-11 composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções BRPI0512583B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/960,516 US7740875B2 (en) 2004-10-08 2004-10-08 Organo-gel formulations for therapeutic applications
US11/066,485 US20060078579A1 (en) 2004-10-08 2005-02-28 Organo-gel formulations for therapeutic applications
US11/150,254 US20060078580A1 (en) 2004-10-08 2005-06-13 Organo-gel formulations for therapeutic applications
PCT/US2005/036064 WO2006042059A1 (en) 2004-10-08 2005-10-11 Organo-gel formulations for therapeutic applications

Publications (3)

Publication Number Publication Date
BRPI0512583A true BRPI0512583A (pt) 2008-03-25
BRPI0512583B1 BRPI0512583B1 (pt) 2018-12-26
BRPI0512583B8 BRPI0512583B8 (pt) 2021-05-25

Family

ID=36148664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512583A BRPI0512583B8 (pt) 2004-10-08 2005-10-11 composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psoríase de unha e de infecções

Country Status (8)

Country Link
US (3) US20060078580A1 (pt)
EP (1) EP1796632A4 (pt)
JP (1) JP2008515911A (pt)
KR (1) KR20070072482A (pt)
AU (1) AU2005294216C1 (pt)
BR (1) BRPI0512583B8 (pt)
CA (1) CA2567575C (pt)
WO (1) WO2006042059A1 (pt)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1526837A1 (de) * 2002-07-24 2005-05-04 Basf Aktiengesellschaft Suspensionen von salzen der ascorbinsäure und ihre verwendung als antioxidantien
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
ES2288133B1 (es) * 2006-06-12 2008-09-16 Maria Cristina Fernandez Rodriguez Composicion topica para el tratamiento de la psoriasis.
EP2526928B1 (en) * 2007-02-05 2018-12-26 Biophile Corporation, Ltd Increased effectiveness of allylamine drug compounds
EP1958639A1 (en) * 2007-02-14 2008-08-20 Polichem S.A. Use of chitosans for the treatment of nail inflammatory diseases
GB0720716D0 (en) * 2007-10-23 2007-12-05 York Pharma Plc Novel formulation
WO2009054992A1 (en) * 2007-10-25 2009-04-30 Ivrea Pharmaceuticals, Inc. Antimicrobial compositions comprising docusate
US20090191138A1 (en) * 2008-01-30 2009-07-30 Mediquest Therapeutics, Inc. Novel topical formulations for improving the appearance of nails
WO2010011650A1 (en) * 2008-07-21 2010-01-28 Imi International Medical Innovations (D/B/A Procris Pharmaceuticals) Stable water-based topical pharmaceutical creams and methods of making and using same
CN102159202A (zh) * 2008-07-23 2011-08-17 靶向递送技术有限公司 施用局部抗真菌制剂治疗真菌感染的方法
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CN102264352A (zh) * 2008-11-14 2011-11-30 阿彻丹尼尔斯米德兰德公司 有机凝胶组合物及其生产方法
JP2012516889A (ja) * 2009-02-05 2012-07-26 ターゲッティド デリバリー テクノロジーズ リミテッド 微生物因子の増殖及び生存能力を低下させる方法
JP5582467B2 (ja) * 2009-04-23 2014-09-03 学校法人日本大学 レシチンおよび尿素を主成分とする逆紐状ミセルから成るオイルゲル
US20100273834A1 (en) * 2009-04-25 2010-10-28 Reza Babapour Treatment of onychomycosis and related compositions including urea
JP5829217B2 (ja) * 2009-12-23 2015-12-09 ヌーボ リサーチ インコーポレイテッドＮｕｖｏ Ｒｅｓｅａｒｃｈ Ｉｎｃ． 高浸透性テルビナフィン製剤
IN2012DN06581A (pt) 2010-03-17 2015-10-23 Novaliq Gmbh
CA2800315A1 (en) * 2010-05-14 2011-11-17 Archer Daniels Midland Company Food compositions comprising organogels
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
RS59484B1 (sr) * 2011-05-03 2019-12-31 Aponia Laboratories Inc Transdermalne kompozicije ibuprofena i postupci za njihovu upotrebu
EP2714010B1 (en) 2011-05-25 2017-03-01 Novaliq GmbH Topical pharmaceutical composition based on semifluorinated alkanes
US9375388B2 (en) 2011-09-23 2016-06-28 Indian Institute Of Technology, Bombay Nanoparticle based cosmetic composition
BR112014017719A8 (pt) 2012-01-23 2017-07-11 Novaliq Gmbh Composições de proteína estabilizada baseadas em alcanos semifluorados
DE202013012742U1 (de) 2012-09-12 2019-01-22 Novaliq Gmbh Zusammensetzungen umfassend Mischungen aus semifluorierten Alkanen
PL3181119T3 (pl) 2012-09-12 2020-01-31 Novaliq Gmbh Kompozycje semifluorowanych alkanów do zastosowania w leczeniu suchego zapalenia spojówki i rogówki
US9452173B2 (en) 2013-01-31 2016-09-27 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9433680B2 (en) 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US8778365B1 (en) 2013-01-31 2014-07-15 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
US9446131B2 (en) 2013-01-31 2016-09-20 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
KR102164169B1 (ko) 2013-02-13 2020-10-12 고쿠리쓰다이가쿠호진 규슈다이가쿠 겔화제 및 오가노겔
EP2815757A1 (en) * 2013-06-17 2014-12-24 Hestia Investments Composition for topical use in prevention and treatment of bacterial and fungal infections of skin and mucosa
WO2015011199A1 (en) 2013-07-23 2015-01-29 Novaliq Gmbh Stabilized antibody compositions
WO2016144121A2 (ko) * 2015-03-12 2016-09-15 동아제약 주식회사 케라틴 조직의 진균감염증 치료를 위한 약제학적 조성물
KR101690765B1 (ko) * 2015-04-17 2016-12-28 동아제약 주식회사 항진균성 활성물질을 포함하는 경피 제제
KR102154415B1 (ko) 2015-09-30 2020-09-10 노바리크 게엠베하 부분불소화 화합물
ES2743502T3 (es) 2015-09-30 2020-02-19 Novaliq Gmbh Compuestos semifluorados y sus composiciones
ES2763121T3 (es) 2016-06-23 2020-05-27 Novaliq Gmbh Método de administración tópica
CN109890374A (zh) 2016-09-22 2019-06-14 诺瓦利克有限责任公司 用于治疗睑缘炎的药物组合物
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
CN111372566A (zh) 2017-09-27 2020-07-03 诺瓦利克有限责任公司 用于治疗眼部疾病的包含拉坦前列素的眼科用组合物
WO2019068763A1 (en) 2017-10-04 2019-04-11 Novaliq Gmbh OPHTHALMIC COMPOSITIONS COMPRISING F6H8
CN112135603B (zh) 2018-03-02 2024-04-16 诺瓦利克有限责任公司 包含奈必洛尔的药物组合物
CN112888443A (zh) 2018-08-01 2021-06-01 爱迪克斯-欧有限公司 用于其在治疗指或趾甲疾病中的使用和/或用于加速指或趾甲生长的具有延长的作用持续时间的可注射组合物
EP3603650A1 (fr) 2018-08-01 2020-02-05 Edix O Sarl Compositions injectables et a duree d'action prolongee pour leur utilisation dans le traitement de maladies de l'ongle et/ou pour accelerer la croissance de l'ongle
CN112839620A (zh) 2018-09-27 2021-05-25 诺瓦利克有限责任公司 脂质屏障修复剂
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
JP7500550B2 (ja) 2018-10-12 2024-06-17 ノバリック ゲーエムベーハー 乾性眼疾患の治療のための眼科用組成物
US11813354B1 (en) * 2019-01-11 2023-11-14 Shear Kershman Laboratories, Inc Trans-mucosal delivery system for testosterone

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3883545A (en) * 1968-08-31 1975-05-13 Hoechst Ag Certain 1-hydroxy-2-pyridones
US4021573A (en) * 1974-04-22 1977-05-03 The Regents Of The University Of California Psoriasis treatment with retinoic acid analogs
US3957971A (en) * 1974-07-29 1976-05-18 Lever Brothers Company Moisturizing units and moisturizing compositions containing the same
US4036970A (en) * 1975-07-28 1977-07-19 Syntex (U.S.A.) Inc. Imidazol-1-yl propane derivatives
CY1410A (en) * 1979-08-22 1988-04-22 Sandoz Ag Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
US5132459A (en) * 1979-08-22 1992-07-21 Sandoz Ltd. Propenylamines, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
FR2502951B1 (fr) 1981-04-06 1985-12-06 Sandoz Sa Compositions pharmaceutiques topiques sous forme d'une micro-emulsion
DE3225706C2 (de) * 1982-07-09 1984-04-26 A. Nattermann & Cie GmbH, 5000 Köln Flüssige Wirkstofformulierungen in Form von Konzentraten für Mikroemulsionen
US5030625A (en) * 1984-11-22 1991-07-09 Sandoz Ltd. Anti-fungal homopropargylamine compounds
DE3582060D1 (de) * 1984-11-22 1991-04-11 Sandoz Ag Homopropargylamine.
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4788061A (en) * 1985-07-05 1988-11-29 Shore Ronald N Extended occlusive treatment of skin disorders
US4764381A (en) * 1985-12-06 1988-08-16 Key Pharmaceuticals, Inc. Percutaneous penetration enhancer of oleic acid and 2-ethyl-1, 3-hexanediol
DE3544983A1 (de) * 1985-12-19 1987-06-25 Hoechst Ag Antimykotisch wirksamer nagellack
US5525635A (en) * 1986-02-04 1996-06-11 Moberg; Sven Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof
US4751245A (en) * 1986-06-25 1988-06-14 E. R. Squibb & Sons, Inc. Antifungal derivatives of N-(6,6-dimethyl-2-hepten-4-ynyl)-1-naphthalenemethanamine and method of using same
US4782059A (en) 1986-09-29 1988-11-01 Merck & Co., Inc. Method of controlling mycotic infections and compositions therefor
GB8630721D0 (en) * 1986-12-23 1987-02-04 Unilever Plc Cosmetic compositions
US5389677B1 (en) * 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US4940586A (en) * 1987-02-26 1990-07-10 Alza Corporation Skin permeation enhancer compositions using sucrose esters
DE3720147A1 (de) * 1987-06-16 1988-12-29 Hoechst Ag Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung
CH681427A5 (pt) 1987-07-01 1993-03-31 Zambon Spa
US5051260A (en) * 1987-07-16 1991-09-24 The Regents Of The University Of California Method and composition for enhancing the cutaneous penetration of pharmacologically active agents
US5045317A (en) * 1987-07-16 1991-09-03 The Regents Of The University Of California Enhancing the cutaneous penetration of pharmacologically active agents
US4920112A (en) * 1988-04-18 1990-04-24 Merck & Co., Inc. Fungicidal compositions and method
US5181914A (en) * 1988-08-22 1993-01-26 Zook Gerald P Medicating device for nails and adjacent tissue
FR2646603B1 (fr) 1989-05-03 1991-07-12 Oreal Composition nettoyante
US5219877A (en) * 1989-09-25 1993-06-15 Bristol-Myers Squibb Company Lauryl alcohol as skin penetration enhancer for topical imidazole agents
JP3116364B2 (ja) * 1989-10-02 2000-12-11 萬有製薬株式会社 エンイン誘導体の製造法
US5356633A (en) * 1989-10-20 1994-10-18 Liposome Technology, Inc. Method of treatment of inflamed tissues
US5741513A (en) * 1990-02-08 1998-04-21 A. Natterman & Cie. Gmbh Alcoholic aqueous gel-like phospholipid composition, its use and topical preparations containing it
DK0514435T3 (da) 1990-02-08 1993-11-29 Nattermann A & Cie Alkoholholdig vandig gelagtig phospholipidsammensætning samt anvendelsen heraf
GB9027433D0 (en) * 1990-12-18 1991-02-06 Merrell Dow Pharma Anti-herpes castanospermine esters
FR2673537B1 (fr) * 1991-03-08 1993-06-11 Oreal Utilisation d'agents de penetration hydrophiles dans les compositions dermatologiques pour le traitement des onychomycoses, et compositions correspondantes.
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
JPH0739325B2 (ja) * 1991-06-24 1995-05-01 株式会社島津製作所 住居用防カビ剤
US5985860A (en) * 1992-06-03 1999-11-16 Toppo; Frank System for transdermal delivery of pain relieving substances
US5318960A (en) * 1992-06-03 1994-06-07 Frank Toppo System for transdermal delivery of pain relieving substances
WO1994023748A1 (en) * 1993-04-08 1994-10-27 The University Of Queensland Administration of vaso-active agent and therapeutic agent
JP2545729B2 (ja) * 1993-05-11 1996-10-23 工業技術院長 メトトレキセート誘導体とピラン共重合体の高分子結合体及びその製造方法
US5698589A (en) * 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
DE4337945A1 (de) * 1993-11-06 1995-05-11 Labtec Gmbh Pflaster zur Behandlung von Nagelmykosen
US5514698A (en) * 1994-03-21 1996-05-07 Ortho Pharmaceutical Corporation Antifungal vaginal cream composition
US5925669A (en) * 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
JP3081766B2 (ja) * 1994-05-06 2000-08-28 東興薬品工業株式会社 角質貯留型抗真菌外用組成物
JP3211892B2 (ja) * 1994-05-27 2001-09-25 セイジィ ファーマスーティカルス インコーポレーテッド 肛門疾患を治療する窒素酸化物供与体及び方法
US5696164A (en) * 1994-12-22 1997-12-09 Johnson & Johnson Consumer Products, Inc. Antifungal treatment of nails
JPH11502509A (ja) * 1995-01-16 1999-03-02 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション 治療用化合物 − 脂肪酸抱合体
US5639740A (en) * 1995-03-10 1997-06-17 Crandall; Wilson Trafton Topical moisturizing composition and method
US5945409A (en) * 1995-03-10 1999-08-31 Wilson T. Crandall Topical moisturizing composition and method
US5654337A (en) * 1995-03-24 1997-08-05 II William Scott Snyder Topical formulation for local delivery of a pharmaceutically active agent
GB9509631D0 (en) * 1995-05-12 1995-07-05 Sandoz Ltd Antifungal combination
US5652256A (en) * 1995-06-06 1997-07-29 Knowles; W. Roy Topical composition for fungal treatment
EP0866683A4 (en) * 1995-09-14 1999-01-07 Sorenson Pharmaceutical Inc MEANS AND METHOD FOR TREATING DISEASE NAILS
NZ280065A (en) * 1995-09-20 1998-04-27 Apotex Inc Preparation of n-alkyl-n-(1-naphthylmethyl)alk-2-en-4-ynylamine derivatives
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US20040039030A1 (en) * 1996-09-27 2004-02-26 Hoechst Akeengesellschaft Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US5807957A (en) * 1996-12-23 1998-09-15 Macrochem Corporation Cationic film-forming polymer compositions, and use thereof in topical agents delivery system and method of delivering agents to the skin
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
AU756136B2 (en) * 1997-06-23 2003-01-02 Queen's University At Kingston Microdose therapy
WO1999003823A2 (en) * 1997-07-15 1999-01-28 Oridigm Corporation Novel polyamine analogues as therapeutic and diagnostic agents
US5993790A (en) * 1997-08-04 1999-11-30 Pedinol Pharmacal Inc. Nail evulsion compositions and method for evulsing nails and treating nail and nail bed infections
US5935577A (en) * 1998-01-23 1999-08-10 Autoimmune Inc. Treatment of autoimmune disease using tolerization in combination with methotrexate
EP1071413B1 (en) * 1998-04-17 2004-06-16 Bertek Pharmaceuticals, Inc. Topical formulations for the treatment of nail fungal diseases
US6231889B1 (en) * 1998-09-21 2001-05-15 Chronorx, Llc Unit dosage forms for the treatment of herpes simplex
US6159977A (en) * 1998-11-16 2000-12-12 Astan, Inc. Therapeutic anti-fungal nail preparation
DE60023660T2 (de) * 1999-02-05 2006-09-07 MediQuest Therapeutics, Inc., Seattle Antizymmodulatoren sowie deren verwendung
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6558695B2 (en) * 1999-12-16 2003-05-06 Dermatrends, Inc. Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
SE0000303D0 (sv) * 2000-01-31 2000-01-31 Xylogen Ab Novel compounds
US6632843B1 (en) * 2000-02-01 2003-10-14 Mark Friedman Treatment of bruxism
DE10011081A1 (de) * 2000-03-09 2001-09-13 Aventis Pharma Gmbh Antiinfektive Wirkstoffkombinationen und ihre Verwendung zur topischen Behandlung von Pilzerkrankungen der Fuß- und Fingernägel
US6485740B1 (en) * 2000-03-14 2002-11-26 Yutoku Pharmaceutical Ind., Co., Ltd. Transdermal methotrexate preparations
IT1318425B1 (it) 2000-03-24 2003-08-25 D B P Dev Biotechnological Pro Impiego del resveratrolo per il trattamento di eczema desquamativo,acne e psoriasi.
US6281239B1 (en) * 2000-04-12 2001-08-28 Bradley Pharmeaceuticals, Inc. Method of treating onychomycosis
PL212660B1 (pl) 2000-10-27 2012-11-30 Leo Pharma As Zasadniczo niewodna zelowa kompozycja farmaceutyczna do podawania na skóre oraz jej zastosowanie
EA200300849A1 (ru) * 2001-02-01 2004-02-26 Байоджен, Инк. Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов
US6585963B1 (en) * 2001-02-15 2003-07-01 Watson Pharmaceuticals, Inc. Nail compositions and methods of administering same
JP4843169B2 (ja) * 2001-02-27 2011-12-21 株式会社Ａｄｅｋａ 殺菌洗浄剤組成物
WO2002076945A1 (en) * 2001-03-09 2002-10-03 Ortho-Mcneil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
GB0108082D0 (en) * 2001-03-30 2001-05-23 Novartis Consumer Health Sa Topical composition
US6638981B2 (en) * 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
US20030091540A1 (en) * 2001-10-16 2003-05-15 Nawaz Ahmad Compositions and methods for delivering antibacterial, antifungal and antiviral ointments to the oral, nasal or vaginal cavity
CA2468539C (en) 2001-10-22 2013-01-08 Michael A. Repka Delivery of medicaments to the nail
US6986896B2 (en) * 2002-03-20 2006-01-17 Bradley Pharmaceuticals, Inc. Method of treating fungal conditions of the skin
US6673842B2 (en) * 2002-03-20 2004-01-06 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis
US6743417B2 (en) * 2002-04-22 2004-06-01 Bradley Pharmaceuticals, Inc. Method of treating onychomycosis with urea and an antioxidant
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
CN1678277B (zh) * 2002-07-29 2010-05-05 艾克里麦德公司 治疗皮肤病的方法和组合物
JP2004083439A (ja) * 2002-08-23 2004-03-18 Ss Pharmaceut Co Ltd 爪用抗真菌外用剤
US6914079B2 (en) * 2002-09-23 2005-07-05 Mediquest Therapeutics, Inc. Polyamine analogs that activate antizyme frameshifting
US7135194B2 (en) * 2002-09-27 2006-11-14 Birnbaum Jay E Subunguicide, and method for treating onychomycosis
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
EP1587519A4 (en) * 2003-01-10 2006-05-31 Threshold Pharmaceuticals Inc TREATMENT OF CANCER WITH 2-DEOXYGLUCOSE
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20060078580A1 (en) 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications

Also Published As

Publication number Publication date
BRPI0512583B8 (pt) 2021-05-25
KR20070072482A (ko) 2007-07-04
AU2005294216B2 (en) 2010-06-24
AU2005294216C1 (en) 2011-02-24
AU2005294216A1 (en) 2006-04-20
WO2006042059A1 (en) 2006-04-20
US20060110342A1 (en) 2006-05-25
US20100305081A1 (en) 2010-12-02
US20060078580A1 (en) 2006-04-13
CA2567575A1 (en) 2006-04-20
EP1796632A1 (en) 2007-06-20
US7776349B2 (en) 2010-08-17
CA2567575C (en) 2009-01-20
BRPI0512583B1 (pt) 2018-12-26
EP1796632A4 (en) 2009-03-11
JP2008515911A (ja) 2008-05-15

Similar Documents

Publication Publication Date Title
BRPI0512583A (pt) composições e métodos de produção das mesmas, de liberação de agente ativo para e através do tecido da epiderme de pessoa ou animal e de tratamento de paciente que sofre de onicomicose, de psorìase de unha e de infecções
SG156624A1 (en) Organo-gel formulations for therapeutic applications
Murdan Drug delivery to the nail following topical application
BRPI0822162B8 (pt) composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal
BRPI0511235A (pt) preparado tópico e método para a administração transdérmica e localização de agentes terapêuticos
AR024516A1 (es) Compuestos bi-aromaticos analogos de la vitamina d, su utilizacion, composicion farmaceutica y composicion cosmetica que comprenden al menos uno de dichos compuestos y utilizacion de dicha composicion cosmetica.
CR9351A (es) Composiciones y metodos para aplicaicon topica y suministro transdermico de toxina botulinica
BR0317747A (pt) Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave
AR049518A1 (es) Composicion farmaceutica que comprende un agente siliconado y dos principios activos solubilizados
BRPI0510806A (pt) formulação do tipo spot-on para a aplicação tópica localizada, utilização de um princìpio ativo e método tratamento cosmético da pele
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
SE8600501D0 (sv) Preparat for behandling av nagelsvamp och seborroiskt eksem
BRPI0414320A (pt) composição para tratamento da pele
BRPI0417666A (pt) composição para tratamento oral ou pessoal, método para administrar um material funcional a um sujeito humano ou animal, e, processo para preparar uma composição para tratamento oral ou pessoal
BRPI0923589A2 (pt) uso de uma composição espumável essencialmente livre de ingredientes farmaceuticamente ativos para o tratamento da pele humana.
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
BR0015924A (pt) Compostos triaromáticos análogos de vitamina d, uso de um composto, composição farmacêutica, composição cosmética e uso de uma composição cosmética
CY1109843T1 (el) Αναλογα της βιταμινης d
BRPI1010861A8 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
US20230338608A1 (en) Dressings comprising platelet lysate
BR0311414A (pt) Agente terapêutico para uma bexiga hiperativa
ATE322878T1 (de) Biotin enthaltende galenische formulierung
BR0015770A (pt) Compostos bicìclicos análogos de vitamina d, uso de um composto, composição farmacêutica, composição cosmética e uso de uma composição cosmética
BRPI0518619A2 (pt) mÉtodo de tratar cÂncer em um mamÍfero, combinaÇço farmacÊutica, uso de uma composiÇço ou combinaÇço farmacÊutica e composiÇço imunogÊnica
UY37497A (es) Formulación tópica que comprende n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamida

Legal Events

Date Code Title Description
B25C Requirement related to requested transfer of rights

Owner name: MEDIQUEST THERAPEUTICS, INC (US)

Free format text: A FIM DE ATENDER A TRANSFERENCIA, REQUERIDA ATRAVES DA PETICAO NO 860140107607 DE 01/07/2014, E NECESSARIO APRESENTAR O DOCUMENTO DE CESSAO DEVIDAMENTE NOTARIZADO E COM A LEGALIZACAO CONSULAR, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA.

B25A Requested transfer of rights approved

Owner name: MQT HOLDINGS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B07A Technical examination (opinion): publication of technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/11/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF